Nimesulid-induced Severe Adverse Reaction of Generalized Bullous Fixed Drug Eruption Type – Case Report
Authors:
E. Březinová 1; V. Thon 2
; S. Zgažarová 1; E. Štrnálová 1; V. Vašků 1; L. Střelec 3; R. Sís 3; H. Jedličková 1
Authors place of work:
I. dermatovenerologická klinika, FN u sv. Anny a LF MU, Brno
přednosta prof. MUDr. Vladimír Vašků, CSc.
1; Ústav klinické imunologie a alergologie, FN u sv. Anny a LF MU, Brno
přednosta prof. MUDr. Jiří Litzman, CSc.
2; Oddělení psychiatricko-neurologické, Psychiatrická nemocnice Brno
primář MUDr. Ivo Černý
3
Published in the journal:
Čes-slov Derm, 89, 2014, No. 5, p. 225-229
Category:
Case interpretation
Summary
The authors describe a case of generalized bullous fixed drug eruption after the systemic use of nimesulide successfully treated by an intravenous immunoglobulin. They discuss differential diagnoses particularly Stevens-Johnson syndrome and toxic epidermal necrolysis and provide an overview of current knowledge on the pathogenesis and treatment of this reaction.
Key words:
generalized bullous fixed drug eruption – toxic epidermal necrolysis – Stevens-Johnson syndrome – intravenous immunoglobulin – apoptosis – severe adverse drug reactions
Zdroje
1. ALLANORE, L., ROUJEAU, J. C. Clinic and Pathogenesis of Severe Bullous Skin Reactions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis. In Pichler, W. J.: Drug Hypersensitivity. Basel: Karger, 2007, p. 267–277.
2. ARAKI, Y., SOTOZONO, C., INATOMI, T. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am. Ophtalmol, 2009, 147, 6, p. 1004–1011.
3. BASTUJI-GARIN, S., RZANY, S., STERN, R. S. Clinical classiffication of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol., 1993, 129, p. 92–96.
4. BASTUJI-GARIN, S., ZAHEDI, M., GUILLAUME, J. C., ROUJEAU, J. C. Toxic Epidermal Necrolysis (Lyell Syndrome) in 77 Elderly Patients. Age and Ageing, 1993, 22, p. 450–456.
5. BRENNER, S., BIALY-GOLAN, A., RUOCCO, V. Drug- -induced pemphigus. Clin. Dermatol., 1998, 16, p. 393–397.
6. BRENNER, S., GOLDBERG, I. Drug-induced pemphigus. Clin. Dermatol., 2011, 29, 4, p. 455–457. doi: 10.1016/j.clindermatol.2011.01.016.
7. CHANG, Y. S., HUANG, F. CH., TSENG, S. H. et al. Erythema Multiforme, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis: Acute Ocular Manifestations, Causes, and Management. Cornea, 2007, 26, 2, p. 123–129.
8. CHATTERJEE, S., PAL, J., BISWAS, N. Nimesulide-induced hepatitis and toxic epidermal necrolysis. J. Postgrad. Med., 2008, 54, p. 150–151.
9. CHAVE, T. A., MORTIMER, N. J., SLADDEN, M. J., HALL, A. P., HUTCHINSON, P. E. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br. J. Dermatol., 2005, 153, p. 241–253.
10. CHIE, S., MAYUMI, U., NORIKO, K. et al. Diagnosis and Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Ocular Complications: Management and Treatment. Ophthalmology, 2009, 116, 4, p. 685–690.
11. CHOI, H. J., KU, J. K., KIM, M. Y. et al. Possible role of Fas/Fas ligand-mediated apoptosis in the pathogenesis of fixed drug eruption. Br. J. Dermatol., 2006, 154, p. 419–425.
12. CHUNG, W., HUNG, S. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis. Journal of Dermatological Science, 2012, 66, p. 190–196.
13. COMPARIN, C., FILHO, G. H., TAKITA, L. C. et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin: a series of three cases. An. Bras. Dermatol., 2012, 87, 3, p. 477–481.
14. DOWNEY, A., JACKSON, C. et al. Toxic epidermal necrolysis: review of pathogenesis and management. J. Am. Acad. Dermatol., 2012, 66, 6, p. 995–1003.
15. ENK, A., EUROPEAN DERMATOLOGY FORUM. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur. J. Dermatol., 2009, 19, 1, p. 90–98. doi: 10.1684/ejd.2008.0580.
16. FAYE, O., ROUJEAU, J. C. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIG). Clinical experience to date. Drugs, 2005, 65, 15, p. 2085–2090.
17. FENG, S., ZHOU, W., ZHANG, J., JIN, P. Analysis of 6 cases of drug-induced pemphigus. Eur. J. Dermatol., 2011, 21, p. 696–699.
18. FRENCH, L. E. Toxic epidermal necrolysis and Stevens Johnson Syndrome: Our current understanding. Allergology International, 2006, 55, 1, p. 9–16.
19. GUNTEN, S., SIMON, H. U. Cell Death Modulation by Intravenous Immunoglobulin. J. Clin. Immunol., 2010, 30, 1, p. 24–30.
20. HAŠKOVÁ, M. Akutní generalizovaná exantematózní pustulóza (AGEP) potvrzená in vivo plátenkovými a prick testy. Čes.-slov. Derm., 1999, 74, 6, s. 260–261.
21. HINTERHUBER, G., BINDER, M., MARQUARD, Y. et al. Enzyme-linked immunosorbent assay for detection of peptide-specific human antidesmoplakin autoantibodies. Br. J. Dermatol., 2005, 153, p. 413–416.
22. HORN, J., THON, V., BARTONKOVA, D. et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin. Immunol., 2007, 122, 2, p. 156–162.
23. JEDLIČKOVÁ, H. Imunofluorescenční vyšetření v dermatologii. Čes.-slov. Derm., 2011, 86, 4, p. 175–184.
24. JEDLIČKOVÁ, H., ZGAŽAROVÁ, S. Polékové exantémy. Dermatol. praxi, 2008, 2, 3, p. 126–129.
25. KORKIJ, W., SOLTANI, K. Fixed drug eruption. A brief review. Arch. Dermatol., 1984, 120, p. 520–524.
26. LAMAND, V., DAUWALDER, O., TRISTAN, A., CASALEGNO, J. S. Epidemiological data of staphylococcal scalded skin syndrome in France from 1997 to 2007 and microbiological characteristicks of Staphylococcus aureus associated strains. Clin. Microbiol. Infect, 2012, 18, E514-521, doi: 10.1111/1469-0691.12053.
27. LIPOVÝ, B., BRYCHTA, P., CHALOUPKOVÁ, Z., SUCHÁNEK, I. Staphylococcal scalded skin syndrome in the Czech Republic: an epidemiological study. Burns, 2012, 38, p. 296–300.
28. LEE, H. Y., LIM, Y. L., THIRUMOORTHY, T., PANG, S. M. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. Br. J. Dermatol., 2013, 169, p. 1304–1309.
29. LIPOVÝ, B., ŘIHOVÁ, H. et al. Toxická epidermální nekrolýza: přehled možností terapie. Hojení ran, 2011, 5, 4, s. 6–12.
30. LIPOWICZ, S., SEKULA, P., INGEN-HOUSZ-ORO, S., SASSOLAS, B., DUNANT, A., ROUJEAU, J. C., MOCKENHAUPT, M. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br. J. Dermatol., 2013, 168, 4, p. 726–732.
31. LYELL, A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br. J. Dermatol., 1956, 68, p. 355–361.
32. MALHEIRO, D., CADINHA, S., RODRIGUES, J., VAZ, M., CASTEL-BRANCO, M. G. Nimesulide-induced fixed drug eruption. Allergol Immunopathol, 2005, 33, 5, p. 285–287.
33. MOCKENHAUPT, M. Severe cutaneous drug reactions. In Burgdorf, W. H. C., Plewig, G., Wolff, H. H. Braun-Falco’s Dermatology (3rd Edition). Heidelberg: Springer Medizin Verlag, 2008, p. 473–483.
34. MOCKENHAUPT, M. The current understanding of Stevens-Johnson syndrome and epidermal necrolysis. Expert Rev. Clin. Immunol., 2011, 7, 6, p. 803–815.
35. MOCKENHAUPT, M., IDZKO, M., GROSBER, M. et al. Epidemiology of staphylococcal scalded skin syndrome in Germany. J. Invest. Dermatol., 2005, 124, p. 700–703.
36. OZKAYA-BAYAZIT, E., BAYAZIT, H., OZARMAGAN, G. Drug related clinical pattern in fixed drug eruption. Eur. J. Dermatol., 2000, 10, 4, p. 288–291.
37. PARK, G. T., QUAN, G., LEE, J. B. Sera from patients with toxic epidermal necrolysis contain autoantibodies to periplakin. Br. J. Dermatol., 2006, 155, p. 337–343.
38. PICHLER, J. W. Drug Hypersensitivity. In Rich, R. Clinical Immunology. Principles and Practice. Third Edition. China: Mosby Elsevier, 2009, p. 709–724.
39. PRINS, C., KERDEL, F. A., PADILLA, R. S. et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch. Dermatol., 2003, 139, 1, p. 26–32.
40. REIPERT, B. M., STELLAMOR, M. T. et al. Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin. Vox sanguinis, 2008, 94, p. 334–341.
41. ROBARO CORDEIRO, M., GONCALO, M., FERNANDES, B. et al. Positive lesional patch tests in fixed drug eruptions from nimesulide. Contact Dermatitis, 2000, 453, p. 307.
42. SHIOHARA, T., MIZUKAWA, Y. A Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur. J. Dermatol., 2007, 17, 3, p. 201–208.
43. TOMKOVÁ, H. Fixní lékový exantém po moxastin teoklátu. Referátový výběr z dermatovenerologie, 2010, 52, 3, p. 76-77.
44. TOMKOVÁ, H., ŠTORK, J. Závažné lékové exantémy. Čes.-slov. derm., 2013, 88, 5, s. 203–212.
45. VIARD, I., WEHRLI, P., BULLANI, R. et al. Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin. Science, 1998, 282, p. 490–492.
46. VIKTORINOVÁ, M. Lékové exantémy po celkovém podání léků. Med. praxi, 2011, 8, 4, p. 181–185.
47. ZIEMER, M., MOCKENHAUPT, M. Severe Drug-Induced Skin Reactions: Clinical Pattern, Diagnostics and Therapy. In Khopkar, U. Skin Biopsy – Perspectives. Rijeka: InTech, 2011, p. 87-116. ISBN: 978-953-307-290-6, Available from: http://www.intechopen.com/books/skin-biopsy-perspectives/severe-drug-induced-skin-reactions-clinical-pattern-diagnostics-and-therapy.
Štítky
Dermatology & STDs Paediatric dermatology & STDsČlánok vyšiel v časopise
Czech-Slovak Dermatology
2014 Číslo 5
Najčítanejšie v tomto čísle
- Structure and Function of Eccrine Sweat Glands and Possibilities of Perspiration Control
- Pretibial Myxoedema
- Cheyletiellosis – a Less Known Parasitosis
- Nimesulid-induced Severe Adverse Reaction of Generalized Bullous Fixed Drug Eruption Type – Case Report